2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.25 Concurrent RB1/TP53 Alterations in Targetable EGFR-Mutant Lung Adenocarcinoma Imply Aggressive Treatment

EP.12A.25 Concurrent RB1/TP53 Alterations in Targetable EGFR-Mutant Lung Adenocarcinoma Imply Aggressive Treatment

Pdf Summary

The study, conducted by Yan Li and colleagues, investigates the impact of concurrent RB1 and TP53 alterations in lung adenocarcinomas with EGFR mutations. These genetic alterations suggest that such cancers may require more aggressive treatment. The research focused on 74 patients with EGFR-mutant lung adenocarcinoma who also had RB1 and TP53 mutations. The patient group comprised 59.21% females and 40.79% males, with an average age of 57 years.<br /><br />Key findings indicated that MYC amplification was the most common additional mutation, present in 13.51% of cases. The majority of patients (52 out of 74) were in an advanced stage of cancer, and the study evaluated the efficacy of first-line treatment with EGFR-Tyrosine Kinase Inhibitors (EGFR-TKI) alone versus combined therapy.<br /><br />Results showed a significant improvement in median progression-free survival (mPFS) and median overall survival (mOS) for patients receiving combined therapy compared to those on EGFR-TKI alone. Specifically, mPFS was 7 months for EGFR-TKI alone versus 14 months for the combined treatment (p=0.039), and mOS was 25 versus 41 months, respectively (although not statistically significant with p=0.127).<br /><br />The study concluded that patients with advanced-stage EGFR-mutant lung adenocarcinoma with concurrent RB1/TP53 alterations appear to benefit more from a therapeutic approach that combines EGFR-TKI with additional treatments. The researchers suggested that a larger prospective study is necessary to confirm these findings.

Asset Subtitle

Yan Li

Meta Tag

Speaker Yan Li

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

RB1 alterations

TP53 mutations

lung adenocarcinoma

EGFR mutations

MYC amplification

EGFR-TKI

progression-free survival

overall survival

combined therapy

prospective study